Regulatory Guidance Review

Contact Veristat Now


Request A Proposal

Contact Us

March 28, 2019

Latest Updates from FDA & EMA

March 2019

Veristat's March 2019 Review of FDA Regulatory Guidances and EMA updatesEach month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in March 2019.

 


FDA Updates

 

FDA has finalized the following guidance documents:

Considerations for the Inclusion of Adolescent Patients in Adult Oncology Trials (finalized 03/12/2019)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM609513.pdf

 

Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (finalized 03/14/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf

 

Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals (finalized 03/14/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM605393.pdf

 

Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research (finalized March 2019)

https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM589416.pdf

 

FDA has issued the following new draft guidance documents:

Bioavailability Studies Submitted in NDAs or INDs – General Considerations (issued 02/25/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM631943.pdf

 

Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations (02/25/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM631941.pdf

 

Quality Considerations for Continuous Manufacturing (issued 02/26/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM632033.pdf

 

Cancer Clinical Trial Eligibility Criteria: Brain Metastases (issued 03/12/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633132.pdf

 

Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies (03/12/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633137.pdf

 

Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients (03/12/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633138.pdf

 

Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections (03/12/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633136.pdf

 

A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers (03/14/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM633316.pdf

  • This is an expansion of the 2013 guidance “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring”; it does not replace the 2013 guidance.

 

Rare Diseases: Natural History Studies for Drug Development (03/22/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM634062.pdf

 

Pediatric Information Incorporated Into Human Prescription Drug and Biological Product Labeling (03/27/19)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM341394.pdf

 


FDA In The News:

 

Statement from FDA Commissioner Scott Gottlieb, M.D., on new strategies to modernize clinical trials to advance precision medicine, patient protections and more efficient product development (03/14/19)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633500.htm

 


EMA Updates:

 

EMA has published a questions-and-answers (Q&A) document on the preparatory work that European Union authorities are doing to prevent medicine shortages due to the United Kingdom’s withdrawal from the EU. (03/26/19)

https://www.ema.europa.eu/en/news/questions-answers-eu-actions-prevent-medicine-shortages-due-brexit

 

As of today, EMA is operating from Amsterdam (03/11/19)

https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam

 

New EudraVigilance system improves reporting of side effects and detection of safety signals (03/27/19)

https://www.ema.europa.eu/en/news/new-eudravigilance-system-improves-reporting-side-effects-detection-safety-signals

 


Explore-More-Image-1